论文部分内容阅读
目的 :联合检测乳腺癌患者中MDR1/P gp、及C erbB 2的表达 ,并探讨MDR1/P gp与C erbB 2的相关性。方法 :采用荧光定量RT PCR(FQ RT PCR)法检测 5 7例乳腺癌、2 0例对照组 (包括 10例乳腺良性疾病、10例癌旁正常组织 )中MDR1基因的表达 ,同时采用免疫组化法检测上述标本中P gp及C erbB 2蛋白的表达。 结果 :乳腺癌患者中MDR1基因扩增率及P gp蛋白阳性率分别为 5 0 .88% (2 9/ 5 7)和 4 2 .11% (2 4 / 5 7) ,与正常对照组相比均具有显著性差异 (P <0 .0 1)。MDR1基因扩增率高于P gp蛋白表达 ,二者呈高度相关 ,但并不完全相符 ;乳腺癌中C erbB 2过表达率为 2 8.0 7% (16 / 5 7) ,正常对照组中无C erbB 2蛋白过表达。MDR1/P gp阳性率与C erbB 2过表达呈正相关。结论 :乳腺癌中存在多药耐药基因MDR1及原癌基因C erbB 2的共表达 ,且其表达呈正相关。上述二种基因的表达 ,与乳腺癌的多药耐药有关。
OBJECTIVE: To detect the expression of MDR1 / P gp and C erbB 2 in breast cancer patients and to explore the relationship between MDR1 / P gp and C erbB 2. Methods: The expression of MDR1 gene in 57 breast cancer patients and 20 control subjects (including 10 benign breast diseases and 10 normal para-cancerous tissues) was detected by fluorescence quantitative RT-PCR (FQ RT-PCR) The above method was used to detect the expression of Pgp and C erbB 2 proteins. Results: The positive rates of MDR1 gene amplification and P gp protein expression in breast cancer patients were 50.88% (29/57) and 42.11% (24/57), respectively. Compared with the normal control group (P <0. 01). The rate of MDR1 gene amplification was higher than that of P gp protein expression, which was highly correlated, but not completely matched. The overexpression rate of C erbB 2 in breast cancer was 28.07% (16/57), while in normal control group C erbB 2 protein overexpression. The positive rate of MDR1 / P gp was positively correlated with C erbB 2 overexpression. Conclusion: The expression of multidrug resistance gene MDR1 and proto-oncogene C erbB 2 in breast cancer is positively correlated. The above two kinds of gene expression, and breast cancer multi-drug resistance.